OVERVIEW

Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice is organized by Rockpointe Corporation.

Release date: May 24, 2019
Expiration date: May 24, 2020

Accreditation:
Credit Designation
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
Cardiovascular disease (CVD) is a leading cause of death in patients with type 2 diabetes mellitus (T2DM). The presence of diabetes also markedly increases the risk of 1-year adverse clinical outcomes (hospitalizations, mortality) in outpatients with heart failure. Multiple clinical trials have been undertaken to address critical issues in the management of CVD and T2DM. Trial findings have shown that the use of newer antihyperglycemic agents can reduce the rate of major cardiovascular events, including heart failure.

Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice will explore the burden of CVD in patients with T2DM, and outline the results from cardiovascular outcomes trials exploring the benefits and risks of antihyperglycemic agents in reducing CVD in patients with T2DM.

Educational Objectives:
This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.
At the conclusion of this activity, participants should be able to:
• Recognize the burden of cardiovascular risk and established CVD in patients with T2DM
• Assess the benefits observed in cardiovascular outcomes trials demonstrating reductions in CVD risk in patients with T2DM, along with appropriate applications in clinical practice